Table 6 Performance of Urine cytology to predict the need for 2nd TURB.
From: Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial)
Group | n | TP | FP | TN | FN | Sensitivity | Specificity | HG | LG | PPV | NPV |
|---|---|---|---|---|---|---|---|---|---|---|---|
(a) Total cohort (n = 171) | |||||||||||
Control cystoscopy | 57 | 1 | 3 | 52 | 1 | 1/2 (50%) | 52/55 (94.5%) | 1/2 (50%) | 1/4 (25%) | 52/53 (98.1%) | |
2nd TURB | 114 | 11 | 4 | 76 | 23 | 11/34 (32.4%) | 76/80 (95.0%) | 9/28 (32.1%) | 2/6 (33.3%) | 11/15 (73.3%) | 76/99 (77.8%) |
Total | 171 | 12 | 7 | 128 | 24 | 12/36 (33.3%) | 128/135 (94.8%) | 9/28 (32.1%) | 3/8 (37.5%) | 12/19 (63.2%) | 128/152 (84.2%) |
(b) Combination of Xpert monitor and urine cytology (neg = Xpert neg AND Cytology neg; pos = Xpert pos AND / OR Cytology pos) in the total cohort (n = 171) | |||||||||||
Control cystoscopy | 57 | 2 | 19 | 36 | 0 | 2/2 (100%) | 36/55 (65.5%) | 2/2 (100%) | 2/21 (9.5%) | 36/36 (100%) | |
2nd TURB | 114 | 29 | 45 | 35 | 5 | 29/34 (85.3%) | 35/80 (43.8%) | 27/28 (96.4%) | 5/6 (83.3%) | 29/74 (39.2%) | 35/40 (87.5%) |
Total | 171 | 31 | 64 | 71 | 5 | 31/36 (86.1%) | 71/135 (52.6%) | 27/28 (96.4%) | 7/8 (87.5%) | 31/95 (32.6%) | 71/76 (93.4%) |
